This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Geer, D. J. Articles by Andreadis, S. T. Search for Related Content PubMed PubMed Citation Articles by Geer, D. J. Articles by Andreadis, S. T.

(American Journal of Pathology. 2005;167:1575-1586.)
© 2005 American Society for Investigative Pathology

Biomimetic Delivery of Keratinocyte Growth Factor upon Cellular Demand for Accelerated Wound Healing in Vitro and in Vivo

David J. Geer^*, Daniel D. Swartz and Stelios T. Andreadis^*

From the Department of Chemical and Biological Engineering,^* Bioengineering Laboratory, and the Women and Children’s Hospital of Buffalo, State University of New York at Buffalo, Amherst, New York

Exogenous keratinocyte growth factor (KGF) significantly enhances wound healing, but its use is hampered by a short biological half-life and lack of tissue selectivity. We used a biomimetic approach to achieve cell-controlled delivery of KGF by covalently attaching a fluorescent matrix-binding peptide that contained two domains: one recognized by factor XIII and the other by plasmin. Modified KGF was incorporated into the fibrin matrix at high concentration in a factor XIII-dependent manner. Cell-mediated activation of plasminogen to plasmin degraded the fibrin matrix and cleaved the peptides, releasing active KGF to the local microenvironment and enhancing epithelial cell proliferation and migration. To demonstrate in vivo effectiveness, we used a hybrid model of wound healing that involved transplanting human bioengineered skin onto athymic mice. At 6 weeks after grafting, the transplanted tissues underwent full thickness wounding and treatment with fibrin gels containing bound KGF. In contrast to topical KGF, fibrin-bound KGF persisted in the wounds for several days and was released gradually, resulting in significantly enhanced wound closure. A fibrinolytic inhibitor prevented this healing, indicating the requirement for cell-mediated fibrin degradation to release KGF. In conclusion, this biomimetic approach of localized, cell-controlled delivery of growth factors may accelerate healing of large full-thickness wounds and chronic wounds that are notoriously difficult to heal.

This article has been cited by other articles:

				J. Y. Liu, H. F. Peng, and S. T. Andreadis Contractile smooth muscle cells derived from hair-follicle stem cells Cardiovasc Res, July 1, 2008; 79(1): 24 - 33. [Abstract] [Full Text] [PDF]

				P. Koria and S. T. Andreadis KGF promotes integrin {alpha}5 expression through CCAAT/enhancer-binding protein-beta Am J Physiol Cell Physiol, September 1, 2007; 293(3): C1020 - C1031. [Abstract] [Full Text] [PDF]

				J. Y. Liu, D. D. Swartz, H. F. Peng, S. F. Gugino, J. A. Russell, and S. T. Andreadis Functional tissue-engineered blood vessels from bone marrow progenitor cells Cardiovasc Res, August 1, 2007; 75(3): 618 - 628. [Abstract] [Full Text] [PDF]

				Y. Zheng, M. Watanabe, T. Kuraishi, S. Hattori, C. Kai, and M. Shibuya Chimeric VEGF-ENZ7/PlGF Specifically Binding to VEGFR-2 Accelerates Skin Wound Healing via Enhancement of Neovascularization Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 503 - 511. [Abstract] [Full Text] [PDF]